New York Times reporters Rebecca Robbins and Gina Kolata with a great write-up (gift link) about Revolution Medicines, daraxonrasib, and the recently FDA-granted expanded access to the drug:

Many patients and families have pleaded for daraxonrasib to be offered through expanded access, saying they do not have time to wait for the drug to win regulatory approval. […]

“We are in a situation where Ian could be dead before this comes on the market,” said Emily Solari, whose husband, Ian Spradlin, 46, has metastatic pancreatic cancer.

Mr. Spradlin, who has already tried three lines of chemotherapy and two experimental drugs, said in an interview last weekend that he would be eager to try daraxonrasib under expanded access if he could get it that way.

“I want to have more time with my kids,” he said.